CELEX: 62017TA0266
Language: en
Date: 2018-09-20 00:00:00
Title: Case T-266/17: Judgment of the General Court of 20 September 2018 — Kwizda Holding v EUIPO — Dermapharm (UROAKUT) (EU trade mark — Opposition proceedings — Application for EU word mark UROAKUT — Earlier national and international figurative marks UroCys — Relative ground for refusal — Lack of likelihood of confusion — Power to amend decisions — Article 8(1)(b) of Regulation No (EC) 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

5.11.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 399/34
            
         
      Judgment of the General Court of 20 September 2018 — Kwizda Holding v EUIPO — Dermapharm (UROAKUT)
      (Case T-266/17) (1)
      
      ((EU trade mark - Opposition proceedings - Application for EU word mark UROAKUT - Earlier national and international figurative marks UroCys - Relative ground for refusal - Lack of likelihood of confusion - Power to amend decisions - Article 8(1)(b) of Regulation No (EC) 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001)))
      (2018/C 399/46)
      Language of the case: German
      
         Parties
      
      
         Applicant: Kwizda Holding GmbH (Vienna, Austria) (represented by: L. Wiltschek, D. Plasser and K. Majchrzak, lawyers)
      
         Defendant: European Union Intellectual Property Office (represented by: S. Hanne, acting as Agent)
      
         Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Dermapharm GmbH (Vienna) (represented by: H. Kunz-Hallstein and R. Kunz-Hallstein, lawyers)
      
         Re:
      
      Action brought against the decision of the Fourth Board of Appeal of EUIPO of 7 March 2017 (Case R 1221/2016-4) concerning opposition proceedings between Dermapharm and Kwizda Holding.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Annuls the decision of the Fourth Board of Appeal of European Union Intellectual Property Office (EUIPO) of 7 March 2017 (Case R 1221/2016-4);
               
            
                  2.
               
               
                  Rejects the opposition brought by Dermapharm GmbH;
               
            
                  3.
               
               
                  Orders EUIPO to bear its own costs and the costs incurred by Kwizda Holding GmbH, including the costs incurred before the Board of Appeal;
               
            
                  4.
               
               
                  Orders Dermapharm to bear its own costs.
               
            
         (1)  OJ C 202, 26.6.2017.